| Year |
Citation |
Score |
| 2023 |
Cowan BA, Olivier K, Tombal B, Wefel JS. Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients' Real-World Insights for Optimizing Outcomes. Advances in Therapy. PMID 37979089 DOI: 10.1007/s12325-023-02721-9 |
0.367 |
|
| 2023 |
Gondi V, Deshmukh S, Brown PD, Wefel JS, Armstrong TS, Tome WA, Gilbert MR, Konski A, Robinson CG, Bovi JA, Benzinger TLS, Roberge D, Kundapur V, Kaufman I, Shah S, et al. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms with Hippocampal Avoidance during Whole-Brain Radiotherapy for Brain Metastases: Final Results of NRG Oncology CC001. International Journal of Radiation Oncology, Biology, Physics. PMID 37150264 DOI: 10.1016/j.ijrobp.2023.04.030 |
0.412 |
|
| 2022 |
Guran E, Hu J, Wefel JS, Chung C, Cata JP. Perioperative considerations in patients with chemotherapy-induced cognitive impairment: a narrative review. British Journal of Anaesthesia. PMID 36270848 DOI: 10.1016/j.bja.2022.08.037 |
0.47 |
|
| 2022 |
Wefel JS, Woods SP. Measuring everyday functioning in patients with brain tumor: The long rows yet to hoe. Neuro-Oncology Practice. 9: 253-254. PMID 35859540 DOI: 10.1093/nop/npac037 |
0.359 |
|
| 2022 |
Lehrer EJ, Jones BM, Dickstein DR, Green S, Germano IM, Palmer JD, Laack N, Brown PD, Gondi V, Wefel JS, Sheehan JP, Trifiletti DM. The Cognitive Effects of Radiotherapy for Brain Metastases. Frontiers in Oncology. 12: 893264. PMID 35847842 DOI: 10.3389/fonc.2022.893264 |
0.454 |
|
| 2022 |
Wefel JS, Ryan CJ, Van J, Jackson JC, Morgans AK. Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors. Cns Drugs. 36: 419-449. PMID 35522374 DOI: 10.1007/s40263-022-00913-5 |
0.395 |
|
| 2022 |
Schagen SB, Tsvetkov AS, Compter A, Wefel JS. Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach? Nature Reviews. Neurology. PMID 35140379 DOI: 10.1038/s41582-021-00617-2 |
0.418 |
|
| 2021 |
Parsons MW, Peters KB, Floyd SR, Brown P, Wefel JS. Preservation of neurocognitive function in the treatment of brain metastases. Neuro-Oncology Advances. 3: v96-v107. PMID 34859237 DOI: 10.1093/noajnl/vdab122 |
0.466 |
|
| 2021 |
Wefel JS, Zhou R, Sulman EP, Boehling NS, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Kahalley LS, Small BJ, Scheurer ME, Bondy ML, Liu Y. Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients. Journal of Neuro-Oncology. PMID 34817796 DOI: 10.1007/s11060-021-03905-5 |
0.352 |
|
| 2021 |
Noll K, King AL, Dirven L, Armstrong TS, Taphoorn MJB, Wefel JS. Neurocognition and Health-Related Quality of Life Among Patients with Brain Tumors. Hematology/Oncology Clinics of North America. 36: 269-282. PMID 34711455 DOI: 10.1016/j.hoc.2021.08.011 |
0.411 |
|
| 2021 |
Brown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer MF, Ghia AJ, Sulman EP, Penas-Prado M, de Groot JF, Heimberger AB, ... ... Wefel JS, et al. A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma. Neuro-Oncology. PMID 33647972 DOI: 10.1093/neuonc/noab040 |
0.31 |
|
| 2020 |
Noll KR, Chen HS, Wefel JS, Kumar VA, Hou P, Ferguson SD, Rao G, Johnson JM, Schomer DF, Suki D, Prabhu SS, Liu HL. Alterations in Functional Connectomics Associated With Neurocognitive Changes Following Glioma Resection. Neurosurgery. PMID 33080024 DOI: 10.1093/neuros/nyaa453 |
0.346 |
|
| 2020 |
Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Bovi JA, Robinson C, Konski A, Khuntia D, Grosshans D, Benzinger TLS, Bruner D, Gilbert MR, Roberge D, et al. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902767. PMID 32058845 DOI: 10.1200/Jco.19.02767 |
0.356 |
|
| 2020 |
Zeng Y, Dong J, Huang M, Zhang JE, Zhang X, Xie M, Wefel JS. Nonpharmacological interventions for cancer-related cognitive impairment in adult cancer patients: A network meta-analysis. International Journal of Nursing Studies. 104: 103514. PMID 32004776 DOI: 10.1016/j.ijnurstu.2019.103514 |
0.337 |
|
| 2019 |
Ryan C, Wefel JS, Morgans AK. A review of prostate cancer treatment impact on the CNS and cognitive function. Prostate Cancer and Prostatic Diseases. PMID 31844181 DOI: 10.1038/s41391-019-0195-5 |
0.303 |
|
| 2019 |
Estevis E, Noll KR, Bradshaw ME, Wefel JS. Driver safety in patients with primary brain tumors. Neuro-Oncology Practice. 6: 490-498. PMID 31832220 DOI: 10.1093/nop/npz014 |
0.373 |
|
| 2019 |
Laack NN, Pugh SL, Brown PD, Fox S, Wefel JS, Meyers C, Choucair A, Khuntia D, Suh JH, Roberge D, Wendland MM, Bruner D. The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy. Neuro-Oncology Practice. 6: 274-282. PMID 31386073 DOI: 10.1093/Nop/Npy038 |
0.435 |
|
| 2019 |
Noll KR, Bradshaw ME, Parsons MW, Dawson EL, Rexer J, Wefel JS. Monitoring of Neurocognitive Function in the Care of Patients with Brain Tumors. Current Treatment Options in Neurology. 21: 33. PMID 31250277 DOI: 10.1007/S11940-019-0573-2 |
0.362 |
|
| 2019 |
van Lonkhuizen PJC, Klaver KM, Wefel JS, Sitskoorn MM, Schagen SB, Gehring K. Interventions for cognitive problems in adults with brain cancer: A narrative review. European Journal of Cancer Care. 28: e13088. PMID 31090162 DOI: 10.1111/ecc.13088 |
0.368 |
|
| 2019 |
Gondi V, Deshmukh S, Brown PD, Wefel JS, Tome W, Armstrong T, Bruner D, Bovi JA, Robinson CG, Khuntia D, Grosshans DR, Konski AA, Roberge D, Kundapur V, Devisetty K, et al. NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM). Journal of Clinical Oncology. 37: 2009-2009. DOI: 10.1200/Jco.2019.37.15_Suppl.2009 |
0.304 |
|
| 2019 |
Wefel JS, Pugh S, Gondi V, Brown PD, Tome W, Armstrong TS, Bruner D, Bovi J, Robinson C, Khuntia D, Grosshans D, Konski A, Roberge D, Kundapur V, Devisetty K, et al. NRG Oncology CC001 Neurocognitive Final Analysis: A Phase III Trial of Hippocampal Avoidance (HA) in Addition to Whole-Brain Radiotherapy (WBRT) Plus Memantine to Preserve Neurocognitive Function (NCF) in Patients With Brain Metastases (BM) Neurosurgery. 66. DOI: 10.1093/Neuros/Nyz310_642 |
0.319 |
|
| 2019 |
Wefel J, Pugh S, Choucair A, Fisher B, Fox S, Meyers C, Ashby L, Mikkelsen T, Glass J, Yu M, Howard S, Movsas B, Mehta M. NCOG-01. NEUROCOGNITIVE FUNCTION (NCF) AND QUALITY OF LIFE (QOL) RESULTS FROM A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH RISK LOW-GRADE GLIOMAS Neuro-Oncology. 21: vi158-vi159. DOI: 10.1093/Neuonc/Noz175.663 |
0.378 |
|
| 2019 |
Armstrong T, Deshmukh S, Brown P, Gondi V, Benzinger T, Gilbert M, Tome W, Wefel J, Bruner D, Roberge D, Kundapur V, Devisetty K, Shah S, Usuki K, Baschnagel A, et al. ACTR-50. PRESERVATION OF NEUROCOGNITIVE FUNCTION & PATIENT-REPORTED SYMPTOMS WITH HIPPOCAMPAL AVOIDANCE (HA) DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: LONG-TERM RESULTS OF NRG ONCOLOGY CC001 Neuro-Oncology. 21: vi24-vi25. DOI: 10.1093/Neuonc/Noz175.092 |
0.358 |
|
| 2018 |
Hardy SJ, Krull KR, Wefel JS, Janelsins M. Cognitive Changes in Cancer Survivors. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 795-806. PMID 30231372 DOI: 10.1200/EDBK_201179 |
0.393 |
|
| 2018 |
Noll KR, Bradshaw ME, Weinberg JS, Wefel JS. Neurocognitive functioning is associated with functional independence in newly diagnosed patients with temporal lobe glioma. Neuro-Oncology Practice. 5: 184-193. PMID 30094046 DOI: 10.1093/nop/npx028 |
0.355 |
|
| 2018 |
Harrison RA, Wefel JS. Neurocognitive Function in Adult Cancer Patients. Neurologic Clinics. 36: 653-674. PMID 30072075 DOI: 10.1016/j.ncl.2018.04.014 |
0.347 |
|
| 2018 |
Noll KR, Bradshaw ME, Rexer J, Wefel JS. Neuropsychological Practice in the Oncology Setting. Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists. 33: 344-353. PMID 29718081 DOI: 10.1093/arclin/acx131 |
0.357 |
|
| 2018 |
Wefel JS, Parsons MW, Gondi V, Brown PD. Neurocognitive aspects of brain metastasis. Handbook of Clinical Neurology. 149: 155-165. PMID 29307352 DOI: 10.1016/B978-0-12-811161-1.00012-8 |
0.406 |
|
| 2018 |
Wefel JS, Deshmukh S, Brown PD, Grosshans DR, Sulman EP, Cerhan JH, Mehta MP, Khuntia D, Shi W, Mishra MV, Suh JH, Laack NN, Chen Y, Curtis A, Laba J, et al. Impact of apolipoprotein E (APOE) genotype on neurocognitive function (NCF) in patients with brain metastasis (BM): An analysis of NRG Oncology’s RTOG 0614. Journal of Clinical Oncology. 36: 2065-2065. DOI: 10.1200/Jco.2018.36.15_Suppl.2065 |
0.328 |
|
| 2018 |
Gondi V, Pugh S, D Brown P, Wefel J, Gilbert M, Bovi J, Robinson C, Tammie B, Tome W, Armstrong T, Bruner D, Khuntia D, Grosshans D, Konski A, Robidoux A, et al. NCOG-01. PRESERVATION OF NEUROCOGNITIVE FUNCTION (NCF) WITH HIPPOCAMPAL AVOIDANCE DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: PRELIMINARY RESULTS OF PHASE III TRIAL NRG ONCOLOGY CC001 Neuro-Oncology. 20: vi172-vi172. DOI: 10.1093/Neuonc/Noy148.716 |
0.306 |
|
| 2017 |
Hansen CC, Smith JB, Mohamed ASR, Mulcahy CF, Wefel JS, Hutcheson KA, Chrane K, Phan J, Frank SJ, Garden AS, Smith BD, Eichelberger H, Anderson C, McCoy C, Horiates M, et al. Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. Head & Neck. PMID 28763137 DOI: 10.1002/Hed.24876 |
0.428 |
|
| 2017 |
Chiu G, Kesler S, Wefel J, Sulman E, Lang F, Grosshans D, Ezhilarasan R, Liu H, Boukelmoune N, Kingsley C, Rao V, Gumin J, Ahmed S, Shpall E, Kavelaars A, et al. Intranasal administration of human mesenchymal stem cells promote recovery from chemoradiation-induced cognitive and functional deficit in mice Brain, Behavior, and Immunity. 66: e25. DOI: 10.1016/J.Bbi.2017.07.097 |
0.457 |
|
| 2016 |
Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS. The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. Journal of Neuro-Oncology. PMID 27848136 DOI: 10.1007/s11060-016-2328-1 |
0.435 |
|
| 2016 |
Noll KR, Ziu M, Weinberg JS, Wefel JS. Neurocognitive functioning in patients with glioma of the left and right temporal lobes. Journal of Neuro-Oncology. PMID 27022915 DOI: 10.1007/s11060-016-2114-0 |
0.378 |
|
| 2016 |
Wefel JS, Noll KR, Scheurer ME. Neurocognitive functioning and genetic variation in patients with primary brain tumours. The Lancet. Oncology. 17: e97-e108. PMID 26972863 DOI: 10.1016/S1470-2045(15)00380-0 |
0.321 |
|
| 2016 |
Hansen C, Chrane K, Gunn G, Mohamed A, Rosenthal D, Wefel J, Phan J, Frank S, Garden A, Smith B, Eichelberger H, Anderson C, McCoy C, Horiates M, Patrick C, et al. Cognitive Function and Patient-Reported Memory Problem Following Radiation Therapy for Cancers at the Skull Base: A Survivorship Study Using the Telephone Interview for Cognitive Status and the MDASI-HN International Journal of Radiation Oncology*Biology*Physics. 94: 967. DOI: 10.1016/J.Ijrobp.2015.12.339 |
0.397 |
|
| 2015 |
Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancré V, Lange M, Castel H. Impact of Cancer and Its Treatment on Cognitive Function: Advances in Research from the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. Journal of Pain and Symptom Management. PMID 26344551 DOI: 10.1016/j.jpainsymman.2015.06.019 |
0.374 |
|
| 2015 |
Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. Ca: a Cancer Journal For Clinicians. 65: 123-38. PMID 25483452 DOI: 10.3322/caac.21258 |
0.342 |
|
| 2015 |
Wefel J, Bradshaw M, Sullaway C, Gilbert M, Armstrong T. NCO-17A BRAIN-PLASTICITY BASED COMPUTERIZED INTERVENTION TO TREAT ATTENTION AND MEMORY PROBLEMS IN ADULT BRAIN TUMOR (BT) SURVIVORS Neuro-Oncology. 17: v149.4-v150. DOI: 10.1093/Neuonc/Nov223.17 |
0.381 |
|
| 2015 |
Wefel J, Sulman E, Zhou R, Liu Y, Scheurer M, Bondy M. NCO-16GENETIC MODULATION OF NEUROCOGNITIVE DECLINE IN GLIOMA PATIENTS Neuro-Oncology. 17: v149.3-v149. DOI: 10.1093/Neuonc/Nov223.16 |
0.303 |
|
| 2015 |
Noll K, Narang S, Martinez J, Rao G, Wefel J, Rao A. NCO-11TUMOR VOLUMETRIC AND TEXTURAL FEATURE PREDICTORS OF NEUROCOGNITIVE IMPAIRMENT IN PATIENTS WITH TEMPORAL LOBE GLIOMA Neuro-Oncology. 17: v148.2-v148. DOI: 10.1093/neuonc/nov223.11 |
0.3 |
|
| 2014 |
Schagen SB, Klein M, Reijneveld JC, Brain E, Deprez S, Joly F, Scherwath A, Schrauwen W, Wefel JS. Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions. Ejc Supplements : Ejc : Official Journal of Eortc, European Organization For Research and Treatment of Cancer ... [Et Al.]. 12: 29-40. PMID 26217164 DOI: 10.1016/j.ejcsup.2014.03.003 |
0.471 |
|
| 2014 |
Wefel JS, Kornet RL, Schagen SB. Systemically treated breast cancer patients and controls: an evaluation of the presence of noncredible performance. Journal of the International Neuropsychological Society : Jins. 20: 357-69. PMID 24607070 DOI: 10.1017/S1355617714000022 |
0.392 |
|
| 2014 |
Wefel JS, Vidrine DJ, Marani SK, Swartz RJ, Veramonti TL, Meyers CA, Hoekstra HJ, Hoekstra-Weebers JEHM, Gritz ER. A prospective study of cognitive function in men with non-seminomatous germ cell tumors Psycho-Oncology. 23: 626-633. PMID 24339329 DOI: 10.1002/Pon.3453 |
0.375 |
|
| 2014 |
Wefel J, Noll K, Rao G, Cahill D. NC-15 * RELATIONSHIPS BETWEEN NEUROCOGNITIVE FUNCTIONING AND IDH1 GENETIC MUTATION STATUS IN MALIGNANT ASTROCYTOMA Neuro-Oncology. 16: v137-v137. DOI: 10.1093/Neuonc/Nou263.15 |
0.312 |
|
| 2014 |
Wefel JS, Schagen SB. Cognitive complaints after breast cancer treatments: Examining the relationship with neuropsychological test performance Breast Diseases. 25: 92-93. DOI: 10.1016/j.breastdis.2014.01.026 |
0.315 |
|
| 2013 |
Schagen SB, Wefel JS. Chemotherapy-related changes in cognitive functioning. Ejc Supplements : Ejc : Official Journal of Eortc, European Organization For Research and Treatment of Cancer ... [Et Al.]. 11: 225-32. PMID 26217131 DOI: 10.1016/j.ejcsup.2013.07.007 |
0.358 |
|
| 2013 |
Johnson DR, Wefel JS. Relationship between cognitive function and prognosis in glioblastoma. Cns Oncology. 2: 195-201. PMID 25057978 DOI: 10.2217/cns.13.5 |
0.435 |
|
| 2013 |
Jones D, Vichaya EG, Wang XS, Sailors MH, Cleeland CS, Wefel JS. Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer. 119: 4188-95. PMID 24105672 DOI: 10.1002/Cncr.28323 |
0.39 |
|
| 2013 |
Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4076-84. PMID 24101048 DOI: 10.1200/Jco.2013.49.6067 |
0.373 |
|
| 2013 |
Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. The Lancet. Oncology. 14: e407-16. PMID 23993385 DOI: 10.1016/S1470-2045(13)70308-5 |
0.323 |
|
| 2013 |
Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, ... ... Wefel JS, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. The Lancet. Oncology. 14: e396-406. PMID 23993384 DOI: 10.1016/S1470-2045(13)70311-5 |
0.305 |
|
| 2013 |
Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology. 15: 1429-37. PMID 23956241 DOI: 10.1093/Neuonc/Not114 |
0.485 |
|
| 2013 |
Wefel JS, Pugh SL, Armstrong TS, Gilbert MR, Won M, Wendland MM, Brachman D, Komaki R, Crocker IR, Robins HI, Lee RJ, Mehta MP. Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825. Journal of Clinical Oncology. 31: 2004-2004. DOI: 10.1200/Jco.2013.31.15_Suppl.2004 |
0.321 |
|
| 2013 |
Armstrong TS, Won M, Wefel JS, Gilbert MR, Pugh SL, Brachman D, Komaki R, Crocker IR, Robins HI, Lee RJ, Mehta MP, Wendland MM. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. Journal of Clinical Oncology. 31: 2003-2003. DOI: 10.1200/Jco.2013.31.15_Suppl.2003 |
0.324 |
|
| 2012 |
Johnson DR, Sawyer AM, Meyers CA, O'Neill BP, Wefel JS. Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro-Oncology. 14: 808-16. PMID 22508762 DOI: 10.1093/neuonc/nos082 |
0.479 |
|
| 2012 |
Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Current Neurology and Neuroscience Reports. 12: 267-75. PMID 22453825 DOI: 10.1007/s11910-012-0264-9 |
0.437 |
|
| 2012 |
Armstrong TS, Wefel JS, Gning I, Acquaye A, Vera-Bolanos E, Gilbert MR, Cleeland CS, Mendoza T. Congruence of primary brain tumor patient and caregiver symptom report. Cancer. 118: 5026-37. PMID 22415423 DOI: 10.1002/Cncr.27483 |
0.391 |
|
| 2012 |
Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, Wefel JS. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. Journal of Neuro-Oncology. 107: 165-74. PMID 21964738 DOI: 10.1007/S11060-011-0723-1 |
0.512 |
|
| 2012 |
Jones D, Vichaya EG, Wefel JS, Thong MS, Mendoza TR, Williams LA, Cleeland CS, Wang XS. Cognitive Impairment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation Blood. 120: 603-603. DOI: 10.1182/Blood.V120.21.603.603 |
0.511 |
|
| 2012 |
Scotland JL, Whittle IR, Deary IJ, De Witte EK, Marien P, Jalali R, Kothawade V, Gupta T, Goswami S, Swamidas J, Racine CA, Lupo JM, Molinaro A, Parks A, Chang SM, ... ... Wefel JS, et al. CLIN-NEURO-COGNITIVE Neuro-Oncology. 14: vi61-vi64. DOI: 10.1093/Neuonc/Nos228 |
0.341 |
|
| 2012 |
Brown P, Shook S, Laack N, Wefel J, Choucair A, Suh J, Roberge D, Kavadi V, Mehta M, Watkins-Bruner D. Memantine for the Prevention of Cognitive Dysfunction in Patients Receiving Whole-brain Radiation Therapy (WBRT): First Report of RTOG 0614, a Placebo-controlled, Double-blind, Randomized Trial International Journal of Radiation Oncology*Biology*Physics. 84: S1-S2. DOI: 10.1016/J.Ijrobp.2012.07.017 |
0.416 |
|
| 2011 |
Wu AS, Witgert ME, Lang FF, Xiao L, Bekele BN, Meyers CA, Ferson D, Wefel JS. Neurocognitive function before and after surgery for insular gliomas. Journal of Neurosurgery. 115: 1115-25. PMID 21905800 DOI: 10.3171/2011.8.Jns11488 |
0.709 |
|
| 2011 |
Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 660-8. PMID 21558074 DOI: 10.1093/Neuonc/Nor024 |
0.392 |
|
| 2011 |
van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. The Lancet. Oncology. 12: 583-93. PMID 21474379 DOI: 10.1016/S1470-2045(11)70057-2 |
0.356 |
|
| 2011 |
Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. The Lancet. Oncology. 12: 703-8. PMID 21354373 DOI: 10.1016/S1470-2045(10)70294-1 |
0.411 |
|
| 2011 |
Wefel JS, Vidrine DJ, Veramonti TL, Meyers CA, Marani SK, Hoekstra HJ, Hoekstra-Weebers JEHM, Shahani L, Gritz ER. Cognitive impairment in men with testicular cancer prior to adjuvant therapy Cancer. 117: 190-196. PMID 20737560 DOI: 10.1002/cncr.25298 |
0.477 |
|
| 2011 |
Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of Radiation Oncology, Biology, Physics. 79: 1487-95. PMID 20399573 DOI: 10.1016/J.Ijrobp.2009.12.061 |
0.303 |
|
| 2011 |
Gonzalez JDSR, Eduardo O, Salvador A, de la Mora Alejandra P, Peiffer AM, Leyrer CM, Greene-Schloesser D, Kearns WT, Hinson WH, Tatter SB, Rapp SR, Robbins ME, Shaw EG, Chan MD, de Groot M, ... ... Wefel JS, ... ... Wefel JS, ... ... Wefel JS, et al. NEURO-COGNITIVE Neuro-Oncology. 13: iii73-iii75. DOI: 10.1093/neuonc/nor166 |
0.342 |
|
| 2010 |
Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 116: 3348-56. PMID 20564075 DOI: 10.1002/cncr.25098 |
0.462 |
|
| 2010 |
Lal L, Wefel JS, Meyers CA, Chang EL, Franzini L, Reasonda LG, Feng C, Swint JM. Cost-effectiveness analysis based on neurocognitive function of a randomized study with stereotactic radiosurgery (SRS) alone versus SRS plus whole-brain radiation therapy (WBRT) for patients with one to three brain metastases. Journal of Clinical Oncology. 28: e16528-e16528. DOI: 10.1200/Jco.2010.28.15_Suppl.E16528 |
0.312 |
|
| 2009 |
Perrier ND, Balachandran D, Wefel JS, Jimenez C, Busaidy N, Morris GS, Dong W, Jackson E, Weaver S, Gantela S, Evans DB, Grubbs EG, Lee JE. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism. Surgery. 146: 1116-22. PMID 19879613 DOI: 10.1016/J.Surg.2009.09.034 |
0.447 |
|
| 2009 |
Benge JF, Perrier ND, Massman PJ, Meyers CA, Kayl AE, Wefel JS. Cognitive and affective sequelae of primary hyperparathyroidism and early response to parathyroidectomy. Journal of the International Neuropsychological Society : Jins. 15: 1002-11. PMID 19807940 DOI: 10.1017/S1355617709990695 |
0.696 |
|
| 2009 |
Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. The Lancet. Oncology. 10: 1037-44. PMID 19801201 DOI: 10.1016/S1470-2045(09)70263-3 |
0.39 |
|
| 2009 |
Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CA. Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists. 24: 689-98. PMID 19767298 DOI: 10.1093/Arclin/Acp060 |
0.406 |
|
| 2009 |
Vredenburgh J, Wefel J, Cloughesy T, Zazzali J, Samant M, Zheng M, Fang L, Das A, Friedman H. 8707 Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study European Journal of Cancer Supplements. 7: 495-496. DOI: 10.1016/S1359-6349(09)71681-7 |
0.32 |
|
| 2008 |
Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy Oncologist. 13: 1285-1295. PMID 19019972 DOI: 10.1634/Theoncologist.2008-0130 |
0.311 |
|
| 2008 |
Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychology Review. 18: 121-31. PMID 18415683 DOI: 10.1007/s11065-008-9058-x |
0.709 |
|
| 2008 |
Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 623-9. PMID 17974553 DOI: 10.1093/annonc/mdm500 |
0.47 |
|
| 2008 |
Wefel JS, Collins R, Kayl AE. Cognitive dysfunction related to chemotherapy and biological response modifiers Cognition and Cancer. 97-114. DOI: 10.1017/CBO9780511545900.009 |
0.342 |
|
| 2007 |
Mittendorf EA, Wefel JS, Meyers CA, Doherty D, Shapiro SE, Lee JE, Evans DB, Perrier ND. Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 13: 338-44. PMID 17669708 DOI: 10.4158/EP.13.4.338 |
0.389 |
|
| 2007 |
Chang EL, Wefel JS, Maor MH, Hassenbusch SJ, Mahajan A, Lang FF, Woo SY, Mathews LA, Allen PK, Shiu AS, Meyers CA. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery. 60: 277-83; discussion 2. PMID 17290178 DOI: 10.1227/01.Neu.0000249272.64439.B1 |
0.387 |
|
| 2006 |
Kayl AE, Wefel JS, Meyers CA. Chemotherapy and cognition: effects, potential mechanisms, and management. American Journal of Therapeutics. 13: 362-9. PMID 16858172 DOI: 10.1097/00045391-200607000-00013 |
0.503 |
|
| 2004 |
Atchison TB, Sander AM, Struchen MA, High WM, Roebuck TM, Contant CF, Wefel JS, Novack TA, Sherer M. Relationship between neuropsychological test performance and productivity at 1-year following traumatic brain injury. The Clinical Neuropsychologist. 18: 249-65. PMID 15587672 DOI: 10.1080/13854040490501475 |
0.305 |
|
| 2004 |
Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer. 101: 466-75. PMID 15274059 DOI: 10.1002/cncr.20393 |
0.412 |
|
| 2004 |
Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 100: 2292-9. PMID 15160331 DOI: 10.1002/cncr.20272 |
0.43 |
|
| 2003 |
Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 3557-8. PMID 12913103 DOI: 10.1200/JCO.2003.07.080 |
0.309 |
|
| 1999 |
Wefel JS, Hoyt BD, Massma PJ. Neuropsychological functioning in depressed versus nondepressed participants with Alzheimer's disease. The Clinical Neuropsychologist. 13: 249-57. PMID 10726596 DOI: 10.1076/Clin.13.3.249.1746 |
0.689 |
|
| Show low-probability matches. |